Navigation Links
Company's Partner Completes Trial Production of a New Antiviral Medicine
Date:10/15/2007

HANGZHOU, China, Oct. 15 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.

HPV infection is common across all races and socio-economic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% of people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression.

According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the United States. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.

About China Biopharma, Inc.

China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese bio-pharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

CONTACT:

China Biopharma, Inc.

Tel: +1 (609) 651-8588

Attn. George Ji

ir@chinabiopharma.net

http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Berbees success is based on companys history and culture
2. APIs New Name Reflects Companys Current Direction
3. Detecting Your Companys Early Trouble Signs
4. Jellyfish partners for sales tracking technology
5. GE Healthcare partners with UNC on breast cancer imaging research
6. Manufacturing partnership will move into biotech and biomedical spaces
7. Fergus joins Baird Venture Partners, Caden Bio
8. Avolte Venture Partners reaches capital goal
9. NimbleGen partners with UK biotech firm
10. Big pharma seeks Wisconsin biotech partnerships
11. Thompson in partnership to build ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):